-
Janssen Biotech: Second indication won for cancer drug Imbruvica
HORSHAM, Pa. — Janssen Biotech on Wednesday announced the Food and Drug Administration has approved Imbruvica (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Imbruvica was first approved in November 2013 for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Both indications are based on an overall response rate. An improvement in survival or disease-related symptoms has not been established.
-
Merz North America launches Mederma PM
GREENSBORO, N.C. — Merz North America recently launched Mederma PM, a new one-of-a-kind scar cream formulated to work at night, when skin naturally regenerates faster.
Mederma PM Intensive Overnight Scar Cream is formulated to complement this nighttime activity with Tripeptol, a skin-nourishing complex with peptides, collagen and antioxidants to promote healthy-looking skin and help skin fight free radical damage.